Table 1.
Demographic information for all participants and disease stage and treatment regimen for patients with breast cancer
| Chemotherapy Group (n=19) | Healthy Control Group (n=14) | |
|---|---|---|
| Age, years | ||
| Mean (SD) | 66.6 (5.24) | 68.1 (5.69) |
| Range | 60–82 | 60–78 |
| Race, N (%) | ||
| White | 13 (68.4%) | 14 (100%) |
| Black | 6 (31.6%) | 0 (0%) |
| Ethnicity, N (%) | ||
| Hispanic or Latina | 2 (10.5%) | 2 (14.3%) |
| Non-Hispanic | 17 (89.5%) | 12 (85.7%) |
| Education, N (%) | ||
| High School | 4 (21.1%) | 1 (7.1%) |
| Some College or junior college | 6 + 4 (52.6%) | 4 + 4 (57.1%) |
| College degree | 3 (15.8%) | 3 (21.4%) |
| Advance degree | 2 (10.5%) | 2 (14.3%) |
| Stage, N (%) | ||
| I | 7 (36.8%) | |
| II | 9 (47.4%) | |
| III | 3 (15.8%) | |
| Regimen, N (%) | ||
| TCa | 10 (52.6%) | |
| TCPHb | 2 (10.5%) | |
| Paclitaxel/trastuzumab | 4 (21.1%) | |
| Carboplatin/paclitaxel | 1 (5.3%) | |
| ddAC-Tc | 1 (5.3%) | |
| TACd | 1 (5.3%) |
a
TC: docetaxel (Taxotere) and cyclophosphamide
b
TCPH: docetaxel (Taxotere), carboplatin, and trastuzumab (Herceptin)
c
ddAC-T: dose dense doxorubicin (Adriamycin) and cyclophosphamide, followed by paclitaxel (Taxol)
d
TAC: docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide